83 related articles for article (PubMed ID: 22413512)
1. [Novel strategies that target hepatokines for treatment of type 2 diabetes].
Misu H; Takamura T; Kaneko S
Nihon Rinsho; 2012 Jan; 70(1):157-63. PubMed ID: 22413512
[TBL] [Abstract][Full Text] [Related]
2. A liver-derived secretory protein, selenoprotein P, causes insulin resistance.
Misu H; Takamura T; Takayama H; Hayashi H; Matsuzawa-Nagata N; Kurita S; Ishikura K; Ando H; Takeshita Y; Ota T; Sakurai M; Yamashita T; Mizukoshi E; Yamashita T; Honda M; Miyamoto K; Kubota T; Kubota N; Kadowaki T; Kim HJ; Lee IK; Minokoshi Y; Saito Y; Takahashi K; Yamada Y; Takakura N; Kaneko S
Cell Metab; 2010 Nov; 12(5):483-95. PubMed ID: 21035759
[TBL] [Abstract][Full Text] [Related]
3. Circulating Concentrations of Insulin Resistance-Associated Hepatokines, Selenoprotein P and Leukocyte Cell-Derived Chemotaxin 2, during an Oral Glucose Tolerance Test in Humans.
Mohri K; Misu H; Takayama H; Ishii KA; Kikuchi A; Lan F; Enyama Y; Takeshita Y; Saito Y; Kaneko S; Takamura T
Biol Pharm Bull; 2019 Mar; 42(3):373-378. PubMed ID: 30606895
[TBL] [Abstract][Full Text] [Related]
4. Identification of hepatokines involved in pathology of type 2 diabetes and obesity.
Misu H
Endocr J; 2019 Aug; 66(8):659-662. PubMed ID: 31366824
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of hepatic expression and secretion of selenoprotein P by metformin.
Speckmann B; Sies H; Steinbrenner H
Biochem Biophys Res Commun; 2009 Sep; 387(1):158-63. PubMed ID: 19576170
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological significance of hepatokine overproduction in type 2 diabetes.
Misu H
Diabetol Int; 2018 Oct; 9(4):224-233. PubMed ID: 30603372
[TBL] [Abstract][Full Text] [Related]
7. [Regulation of glucose metabolism by liver-derived secretory proteins 'hepatokines'].
Misu H; Takamura T
Nihon Rinsho; 2012 May; 70 Suppl 3():207-11. PubMed ID: 22768521
[No Abstract] [Full Text] [Related]
8. Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models.
Mita Y; Nakayama K; Inari S; Nishito Y; Yoshioka Y; Sakai N; Sotani K; Nagamura T; Kuzuhara Y; Inagaki K; Iwasaki M; Misu H; Ikegawa M; Takamura T; Noguchi N; Saito Y
Nat Commun; 2017 Nov; 8(1):1658. PubMed ID: 29162828
[TBL] [Abstract][Full Text] [Related]
9. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
10. The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice.
Huang H; Iida KT; Sone H; Yokoo T; Yamada N; Ajisaka R
J Endocrinol; 2006 Jun; 189(3):643-53. PubMed ID: 16731794
[TBL] [Abstract][Full Text] [Related]
11. A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure.
Deng J; Wang B; Cao Y; Zhu L
Med Hypotheses; 2011 Feb; 76(2):234-6. PubMed ID: 21071152
[TBL] [Abstract][Full Text] [Related]
12. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3.
Koo SH; Satoh H; Herzig S; Lee CH; Hedrick S; Kulkarni R; Evans RM; Olefsky J; Montminy M
Nat Med; 2004 May; 10(5):530-4. PubMed ID: 15107844
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Liu G; Trevillyan JM
Curr Opin Investig Drugs; 2002 Nov; 3(11):1608-16. PubMed ID: 12476961
[TBL] [Abstract][Full Text] [Related]
14. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
Cho CY; Koo SH; Wang Y; Callaway S; Hedrick S; Mak PA; Orth AP; Peters EC; Saez E; Montminy M; Schultz PG; Chanda SK
Cell Metab; 2006 May; 3(5):367-78. PubMed ID: 16679294
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
[TBL] [Abstract][Full Text] [Related]
16. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
DeFronzo RA
Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
[TBL] [Abstract][Full Text] [Related]
17. Separate influences of insulin and hyperglycemia on hepatic drug metabolism in mice with genetic and chemically induced diabetes mellitus.
Knodell RG; Handwerger BS; Morley JE; Levine AS; Brown DM
J Pharmacol Exp Ther; 1984 Jul; 230(1):256-62. PubMed ID: 6379147
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic effects of Artemisia sphaerocephala Krasch. gum, a novel food additive in China, on streptozotocin-induced type 2 diabetic rats.
Xing XH; Zhang ZM; Hu XZ; Wu RQ; Xu C
J Ethnopharmacol; 2009 Sep; 125(3):410-6. PubMed ID: 19635546
[TBL] [Abstract][Full Text] [Related]
19. Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples.
Sugiyama M; Kikuchi A; Misu H; Igawa H; Ashihara M; Kushima Y; Honda K; Suzuki Y; Kawabe Y; Kaneko S; Takamura T
PLoS One; 2018; 13(3):e0194798. PubMed ID: 29596463
[TBL] [Abstract][Full Text] [Related]
20. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
